SCHEMBL7201292

SCHEMBL7201292

NC(=O)N1CCC(S(=O)(=O)c2ccc(OCc3ccccn3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.44
ADAMTS4 O75173 6/20 0.41
MMP13 P45452 9/20 0.39
MMP1 P03956 7/20 0.39
ALOX5 P09917 1/20 0.39
MMP14 P50281 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
CNR1 P21554 1/20 0.37
LCK P06239 1/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203984 0.88 MMP1 (0.45) PARP10ADAMTS4MMP13MMP1MMP14
SCHEMBL7205946 0.85 MMP1 (0.39) ADAMTS4MMP13MMP1MMP14ALDH1A1
SCHEMBL7202584 0.85 RORC (0.46) ADAMTS4MMP13MMP1MMP14RORC
SCHEMBL7206504 0.84 MMP1 (0.47) PARP10ADAMTS4MMP13MMP1MMP14
SCHEMBL7200542 0.84 ADAMTS4 (0.42) ADAMTS4MMP13MMP1MMP14LCK
SCHEMBL7202626 0.84 MMP1 (0.57) ADAMTS4MMP13MMP1
SCHEMBL7206509 0.84 SCN3A (0.45) PARP10ADAMTS4MMP13MMP1
SCHEMBL7208181 0.84 MMP13 (0.56) ADAMTS4MMP13MMP1MMP14
SCHEMBL7202625 0.83 CCR6 (0.39) MMP13MMP1
SCHEMBL7207163 0.83 MMP1 (0.45) PARP10MMP13MMP1MMP14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 PARP10 1359/4885ADAMTS4 26/4885MMP13 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.